Citi on Zimmer Biomet (ZBH): Opening Upside 90-Day Catalyst Watch

Citi analyst Joanna Wuensch reiterated a Neutral rating and $130.00 price target on Zimmer Biomet (NYSE: ZBH).

"Based on management commentary, our attendance at the AAOS meeting, and our proprietary physician survey it does seem like there is momentum under the recovery. While we are encouraged, we are cautious, as the so-called recovery trade has had several spits and starts along the way. In addition, Zimmer Biomet is positioned to benefit from several new products, not the least of which is its Persona OsseoTI Keel Tibia cementless knee (which carries a 10-15% ASP premium and is compatible with the Rosa robotic system) and easing pricing headwinds. Combined,we suggest that the 1Q23 is stacking up to be a strong one for othopaedics, and we are opening a Positive Catalyst Watch on ZBH."

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $129.20 yesterday.

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
• Bullish (BLSH) PT Lowered to $30 at Rosenblatt